You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
FIND said it will announce agreements that will enable the distribution of more than 250 million rapid antigen tests per year to low- and middle-income countries.
The firms are focusing an initial program on the development of a companion diagnostic test for HiberCell’s immunotherapy, Imprime PGG.
The companies aim to create new products enabling faster access to predictive information used in treatment planning for patients with breast cancer.
The firms are using the technology, previously employed by Biocept exclusively for blood-based cancer testing, to develop a highly sensitive COVID-19 diagnostic.
The companies will combine the Binx io diagnostic platform with Sherlock Bio's CRISPR technology to create an easy-to-use rapid test for the point of care.
The partners are planning to develop and commercialize UroMap, a urine-based gene-expression test for acute cellular rejection in kidney transplant recipients.
The firms are developing clinical and RUO workflows that use NGS for pathogen identification and will comarket IDbyDNA's Explify data platform.
Illumina will grant Roche rights to develop and distribute IVD tests on its Dx sequencing instruments, while Roche will help expand the CDx claims for Illumina's solid tumor panel.
ArcherDx will develop in vitro diagnostic tests, including companion diagnostics, to run on Illumina's NextSeq 550Dx next-generation sequencing system.
The firms will codevelop companion diagnostics for anti-PD1/PD-L1 immunotherapy treatments for cancer.